Finding out that the medication you’ve been taking every morning—the one your doctor prescribed to control your blood pressure—might not have been properly dissolving inside your body can be unsettling. In essence, the FDA is currently informing about 13,567 households nationwide. A recent recall of chlorthalidone tablets has been categorized by the agency as a Class II event, which indicates that there is a genuine but minimal risk of health effects. Not disastrous. However, it’s also nothing.
The recalled product, chlorthalidone 25mg in 100-tablet bottles, was produced by Inventia Healthcare Limited, an Indian pharmaceutical company with more than 40 years of experience in the generic market. The particular batch, RISA24002, which expires in April 2027, did not meet the dissolution specifications. It’s a technical term, but once you understand what it means, it’s simple and somewhat concerning: the medication is in the tablet, but it’s not properly releasing into your body. What your body cannot access, it cannot absorb.
The timing of this specific recall makes it more difficult to ignore. Inventiva has recalled identical-strength chlorthalidone tablets that were sold in the same market for the same reason twice in about three months. Over 11,000 bottles were removed during the June 2026 recall. At that point, stability testing at the 18-month mark had identified a problem: dissolution had fallen to 78%, below the necessary 80% threshold, and the active drug was measured at 91.5%, just below the permitted range of 92% to 108%. At the time, the company claimed to have discovered no anticipated effects on patients. Most people assumed it was a one-time quality issue and moved on. Then September came.
Here, it’s difficult to ignore the pattern. Even though there are currently no conclusive answers, two recalls involving the same medication, manufacturer, and failure mechanism raise important questions. It’s still unclear if this is an unfortunate coincidence in production batches or a systemic quality problem at the manufacturing level. Although the precise test values for this second recall have not been made public in the same level of detail as June’s findings, the FDA’s enforcement report mentions failed dissolution for the new batch.
The practical concern is genuine for patients. An estimated 120 million Americans, or nearly half of the population, suffer from high blood pressure, which is the main reason chlorthalidone, a diuretic, is prescribed. It functions by encouraging the kidneys to remove extra salt and fluid from the blood. It works when it dissolves properly. Blood pressure that ought to be under control might not be when it doesn’t dissolve properly. Following the June recall, Stanford hypertension specialist Dr. Vivek Bhalla pointed out that dissolution failures can result in patients receiving less than the intended therapeutic dose, potentially leaving blood pressure poorly managed without anyone realizing it. Seldom do symptoms of high blood pressure appear. While their cardiovascular system silently endures the strain, a person taking a weakened pill may feel perfectly normal.
The advice itself—don’t simply stop taking the medication—makes this situation especially challenging for patients. Jennifer Young, a lead medication safety specialist at the Institute for Safe Medication Practices, has made it clear that stopping a blood pressure medication suddenly can be dangerous. Before making any decisions, it is best to compare the batch code on your bottle with the recall details and then give your doctor or pharmacist a call. Although it may sound bureaucratic, that is actually the safest course of action. Since this September recall is completely different from the June recall, patients who have refilled their prescriptions since then should exercise extra caution. Just because you cleared your bottle in the summer doesn’t mean your current supply is safe.
It’s important to comprehend the context of the FDA’s Class II designation. It does not imply that people have been hurt or that the medication is tainted. It indicates that there is a chance of transient or reversible health effects and that significant harm is deemed unlikely. However, “remote but possible” is a phrase that should be taken seriously rather than dismissed by someone who is managing a chronic condition. The medical community believes that although the system detected this in time—twice so far—two catches in three months is more than anyone would want.
The practical steps are straightforward for the time being. Examine your bottle. Look for NDC 64980-599-01 and batch code RISA24002. Pick up the phone if it matches. Usually, your pharmacist can quickly confirm and set up a replacement. It’s a minor annoyance compared to something that subtly matters a lot: the effectiveness of the medication you take each morning.
FAQs
1. Which specific batch of chlorthalidone has been recalled?
Batch code RISA24002, expiring April 2027, in 100-tablet 25mg bottles.
2. Why were these chlorthalidone tablets recalled?
The tablets failed dissolution specifications, meaning the drug doesn’t release properly for absorption.
3. Is this the first time Inventia has recalled chlorthalidone?
No — a separate June 2026 recall already pulled over 11,000 bottles.
4. Should I stop taking my medication if my bottle is affected?
No — contact your doctor or pharmacist before making any medication changes.
5. How do I know if my bottle is part of the recall?
Check your label for NDC 64980-599-01 and batch code RISA24002.